P435 Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study
Geert D’Haens(Amsterdam University Medical Centers), Séverine Vermeire(KU Leuven), Fabio Cataldi(Pfizer (United States)), Edward V. Loftus(Mayo Clinic), Wen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), B Huang(AbbVie (United States)), Peter Higgins(Michigan Medicine), Remo Panaccione(University of Calgary), Wenhui Xie(University of Washington), Julián Panés(Hospital Clínic de Barcelona)
Cited by 1
Related Papers
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
|Gastroenterology|1998|865